Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Capital Employed (2016 - 2025)

Ligand Pharmaceuticals' Return on Capital Employed history spans 15 years, with the latest figure at 0.04% for Q2 2025.

  • For Q2 2025, Return on Capital Employed fell 2.0% year-over-year to 0.04%; the TTM value through Jun 2025 reached 0.04%, down 2.0%, while the annual FY2024 figure was 0.03%, 4.0% down from the prior year.
  • Return on Capital Employed for Q2 2025 was 0.04% at Ligand Pharmaceuticals, up from 0.07% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.08% in Q4 2021 and bottomed at 0.07% in Q1 2025.
  • The 5-year median for Return on Capital Employed is 0.02% (2023), against an average of 0.01%.
  • The largest annual shift saw Return on Capital Employed rose 7bps in 2021 before it decreased -7bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.08% in 2021, then plummeted by -48bps to 0.04% in 2022, then crashed by -64bps to 0.02% in 2023, then crashed by -258bps to 0.02% in 2024, then tumbled by -60bps to 0.04% in 2025.
  • Per Business Quant, the three most recent readings for LGND's Return on Capital Employed are 0.04% (Q2 2025), 0.07% (Q1 2025), and 0.02% (Q4 2024).